Pharmaceutical compositions of a PD-1 antibody and use of the same
US12364756B2 · kind B2 · utility
0Cited by
1References
66Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2022 |
| Grant date | Jul 22, 2025 |
| Priority date | — |
| Expiry date | May 26, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is provides pharmaceutical compositions, for storage and administration, comprising a human PD-1 (“hPD-1”) antibody (“retifanlimab”) and buffering agents. The disclosure further provides containers and kits comprising such pharmaceutical compositions. The disclosure further provides the use of such pharmaceutical compositions, containers, and kits containing retifanlimab in the treatment of a cancer, and in certain aspects treatment of a cancer expressing PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.